Skip to content
Rewriting Rare Disease R&D with Foundation Models episode artwork

Feb 5, 2026 26 min

Rewriting Rare Disease R&D with Foundation Models

from RARECast

Drug development has long been a costly, trial-and-error effort, with nine out of ten clinical programs failing despite major scientific advances. One reason is that biological information remains fragmented in silos, and traditional R&D approaches often rely on narrow, task-specific datasets. Bioptimus aims to change this by using AI to build a foundation model that integrates multimodal, multiscale biological data into a single body of knowledge. The approach has particular promise for rare diseases, where patient numbers and data are scarce, preclinical models are poor, and development economics are challenging. We spoke with Jean-Philippe Vert, co-founder and CEO of Bioptimus, about the inherent messiness of biology, the potential to transform rare disease drug development with a foundation model, and how uncovering similarities between conditions could enable repurposing of existing drugs.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Rewriting Rare Disease R&D with Foundation Models

0:00 26:30

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of RARECast?

This episode is 26 minutes long.

When was this RARECast episode published?

This episode was published on February 5, 2026.

Can I download this RARECast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.